This segment focuses on the research, development, and clinical trials of immunotherapies for various cancers and infectious diseases. Agenus leverages its proprietary platforms to discover and develop novel antibody-based therapeutics, including checkpoint modulators and cancer vaccines. Research activities include preclinical studies, clinical trial design and execution, and biomarker identification. The company utilizes advanced technologies such as antibody engineering, immune cell profiling, and translational research to improve patient outcomes. This segment aims to address unmet medical needs in oncology and infectious diseases by developing innovative treatments that harness the power of the immune system. Partnerships and collaborations are crucial for advancing clinical programs and expanding the therapeutic pipeline.

This segment focuses on the development and commercialization of vaccine adjuvants and related technologies. Agenus has developed the QS-21 Stimulon adjuvant, which is licensed to GSK and used in their AREXVY vaccine. Research and development activities include optimizing adjuvant formulations, exploring new applications, and conducting clinical trials to demonstrate efficacy and safety. The company utilizes advanced technologies in immunology and formulation science to enhance the immune response to vaccines. This segment aims to improve vaccine efficacy and expand access to life-saving vaccines. The market positioning is strong due to the established partnerships and the proven efficacy of the QS-21 adjuvant. Future opportunities include expanding the adjuvant portfolio and exploring new vaccine applications. Regulatory and clinical aspects are critical, with a focus on obtaining approvals from regulatory agencies such as the FDA.